LONDON--(BUSINESS WIRE)--The European non-Hodgkin’s lymphoma (NHL) therapeutics market has been monopolised by MabThera for a number of years. Although CHOP chemotherapy is the major treatment for all forms of NHL, it is highly genericised with limited prospects for revenue growth. However, market dynamics are poised to change in the near future due to the anticipated launch of many promising pipeline drugs currently in phase 3 of their development.
